[Form 4] ABBOTT LABORATORIES Insider Trading Activity
Rhea-AI Filing Summary
ABBOTT LABORATORIES director Daniel J. Starks bought additional company stock and received new equity awards. He made an open-market purchase of 10,000 common shares at an average price of $92.6537 per share, bringing his direct holding to 6,751,103 common shares.
Starks also received a grant of 2,286 restricted stock units under Abbott’s 2026 Incentive Stock Program, payable one-for-one in common shares upon separation from service, death, or a change in control. In addition, he was granted stock options for 7,105 common shares at an exercise price of $91.86 per share, expiring in 2036. Separately, 258 common shares are held indirectly in the Alynne Starks 2012 Irrevocable Trust, for which he is the sole trustee.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 12,286 shares
Net Buy
4 txns
Insider
STARKS DANIEL J
Role
Director
Bought
10,000 shs ($927K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common shares without par value | 10,000 | $92.6537 | $927K |
| Grant/Award | Option (right to buy) | 7,105 | $0.00 | $0.00 |
| Grant/Award | Common shares without par value | 2,286 | $0.00 | $0.00 |
| holding | Common shares without par value | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 7,105 shares (Direct);
Common shares without par value — 6,751,103 shares (Direct);
Common shares without par value — 258 shares (Indirect, Alynne Starks 2012 Irrevocable Trust)
Footnotes (4)
- F1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.43 to $93.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3. Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
- F4. Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
Key Figures
Open-market purchase: 10,000 shares at $92.6537
Direct holdings after purchase: 6,751,103 shares
Restricted stock units granted: 2,286 RSUs
+4 more
7 metrics
Open-market purchase
10,000 shares at $92.6537
Common shares bought on April 27, 2026
Direct holdings after purchase
6,751,103 shares
Common shares held directly after reported transactions
Restricted stock units granted
2,286 RSUs
Award under Abbott Laboratories 2026 Incentive Stock Program
Stock options granted
7,105 options
Right to buy common shares granted April 24, 2026
Option exercise price
$91.86 per share
Exercise price for 7,105 stock options
Option expiration
April 23, 2036
Expiration date of granted stock options
Indirect trust holdings
258 shares
Common shares held in Alynne Starks 2012 Irrevocable Trust
Key Terms
Restricted stock unit award, Abbott Laboratories 2026 Incentive Stock Program, change in control, Irrevocable Trust, +2 more
6 terms
Restricted stock unit award financial
"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
Abbott Laboratories 2026 Incentive Stock Program financial
"award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"
change in control financial
"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Irrevocable Trust financial
"Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
Stock option financial
"Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Rule 16b-3 financial
"transaction exempt from Section 16 under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Daniel J. Starks do in this Abbott (ABT) Form 4 filing?
Daniel J. Starks reported buying 10,000 Abbott common shares in the open market and receiving new equity awards. The filing also updates his total direct share ownership and notes indirect holdings in a family trust.
What equity awards did Daniel J. Starks receive from Abbott (ABT)?
He received 2,286 restricted stock units under Abbott’s 2026 Incentive Stock Program and stock options for 7,105 common shares at a $91.86 exercise price. Both awards are compensation-related rather than open-market purchases.
How do Daniel J. Starks’ restricted stock units in Abbott (ABT) vest or pay out?
The 2,286 restricted stock units will be paid in Abbott common shares on a one-to-one basis upon the earlier of his separation from service, death, or a change in control, as defined in Abbott’s 2026 Incentive Stock Program.
What are the key terms of Daniel J. Starks’ Abbott (ABT) stock options?
He was granted stock options covering 7,105 common shares with a $91.86 exercise price. These options were granted under Abbott’s 2026 Incentive Stock Program and are scheduled to expire on April 23, 2036.